A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Eli Lilly ( LLY 2.92%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.